Two phase I/II clinical trials (NCT02252146 and NCT02363439) in MYD88-positive DLBCL and WM patients have been performed, with the results showing that IMO-8400 is well tolerated [71]. Here, MYD88 is linked to diffuse large B-cell lymphoma.